CEBPβ regulation of endogenous IGF-1 in adult sensory neurons can be mobilized to overcome diabetes-induced deficits in bioenergetics and axonal outgrowth

Cell Mol Life Sci. 2022 Mar 17;79(4):193. doi: 10.1007/s00018-022-04201-9.

Abstract

Aberrant insulin-like growth factor 1 (IGF-1) signaling has been proposed as a contributing factor to the development of neurodegenerative disorders including diabetic neuropathy, and delivery of exogenous IGF-1 has been explored as a treatment for Alzheimer's disease and amyotrophic lateral sclerosis. However, the role of autocrine/paracrine IGF-1 in neuroprotection has not been well established. We therefore used in vitro cell culture systems and animal models of diabetic neuropathy to characterize endogenous IGF-1 in sensory neurons and determine the factors regulating IGF-1 expression and/or affecting neuronal health. Single-cell RNA sequencing (scRNA-Seq) and in situ hybridization analyses revealed high expression of endogenous IGF-1 in non-peptidergic neurons and satellite glial cells (SGCs) of dorsal root ganglia (DRG). Brain cortex and DRG had higher IGF-1 gene expression than sciatic nerve. Bidirectional transport of IGF-1 along sensory nerves was observed. Despite no difference in IGF-1 receptor levels, IGF-1 gene expression was significantly (P < 0.05) reduced in liver and DRG from streptozotocin (STZ)-induced type 1 diabetic rats, Zucker diabetic fatty (ZDF) rats, mice on a high-fat/ high-sugar diet and db/db type 2 diabetic mice. Hyperglycemia suppressed IGF-1 gene expression in cultured DRG neurons and this was reversed by exogenous IGF-1 or the aldose reductase inhibitor sorbinil. Transcription factors, such as NFAT1 and CEBPβ, were also less enriched at the IGF-1 promoter in DRG from diabetic rats vs control rats. CEBPβ overexpression promoted neurite outgrowth and mitochondrial respiration, both of which were blunted by knocking down or blocking IGF-1. Suppression of endogenous IGF-1 in diabetes may contribute to neuropathy and its upregulation at the transcriptional level by CEBPβ can be a promising therapeutic approach.

Keywords: Diabetic neuropathy; Dorsal root ganglia; IGF-1; Mitochondria; NFAT1; Neurite outgrowth; Neurotrophic factor.

MeSH terms

  • Aging / metabolism*
  • Animals
  • Antibodies, Neutralizing / pharmacology
  • Axons / drug effects
  • Axons / metabolism
  • Axons / pathology*
  • Base Sequence
  • CCAAT-Enhancer-Binding Protein-beta / genetics
  • CCAAT-Enhancer-Binding Protein-beta / metabolism*
  • Cell Respiration / drug effects
  • Cells, Cultured
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / metabolism*
  • Diabetes Mellitus, Experimental / pathology*
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / pathology
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / pathology
  • Energy Metabolism* / drug effects
  • Ganglia, Spinal / drug effects
  • Ganglia, Spinal / metabolism
  • Gene Expression Regulation / drug effects
  • Glycolysis / drug effects
  • HEK293 Cells
  • Humans
  • Insulin-Like Growth Factor I / genetics
  • Insulin-Like Growth Factor I / metabolism*
  • Liver / metabolism
  • Male
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • NFATC Transcription Factors / metabolism
  • Neuronal Outgrowth / drug effects
  • Polymers / metabolism
  • Promoter Regions, Genetic / genetics
  • Protein Transport / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Sensory Receptor Cells / metabolism*
  • Sensory Receptor Cells / pathology
  • Signal Transduction / drug effects

Substances

  • Antibodies, Neutralizing
  • CCAAT-Enhancer-Binding Protein-beta
  • Cebpb protein, rat
  • NFATC Transcription Factors
  • Polymers
  • polyol
  • Insulin-Like Growth Factor I